The rising interest in potent weight management has resulted in considerable research into novel treatments. Currently, Retatrutide, a twin-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activator , has shown promising results in patient trials, implying potential for substantial weight reduct